March 6, 2018 / 1:16 PM / 9 months ago

BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013

March 6 (Reuters) - Fibrocell Science Inc:

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

* FIBROCELL SCIENCE - U.S. FDA GRANTED IND APPLICATION FOR FCX-013 TO BEGIN CLINICAL TRIALS FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

* FIBROCELL SCIENCE - EXPECTS TO INITIATE ENROLLMENT FOR OPEN LABEL, SINGLE ARM PHASE 1/2 CLINICAL TRIAL IN Q3 2018 FOR FCX-013

* FIBROCELL SCIENCE- INTENDS TO INCLUDE PEDIATRIC PATIENTS IN PHASE 2 POST APPROVAL OF SAFETY AND ACTIVITY DATA FROM ADULT PHASE 1 PATIENTS TO FDA Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below